Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Canbridge PharmaceuticalsHKSE:01228 +2.50%48 Gross Margin % is 78.98% as of Dec. 2025, which is 27% above its 10-year median of 62.37. GuruFocus rates HKSE:01228 with a GF Score™ of 48/100 and a GF Value™ of HK$0.38 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 733 Biotechnology companies, Canbridge Pharmaceuticals ranks better than 65.89% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Canbridge Pharmaceuticals had a gross margin of 78.98% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Canbridge Pharmaceuticals Gross Margin % Related Terms
Canbridge Pharmaceuticals Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:01228 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Canbridge Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Canbridge Pharmaceuticals Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Canbridge Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Canbridge Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Canbridge Pharmaceuticals (HKSE:01228) has a Gross Margin % of 78.98% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Canbridge Pharmaceuticals and its competitors. This is 27% above median its historical median of 62.37. Over the past decade, Canbridge Pharmaceuticals' Gross Margin % has ranged from 57.16 to 74.70. According to the industry distribution chart, Canbridge Pharmaceuticals ranks #250 out of 733 companies in the Biotechnology industry, placing it in the top 34.1%.
Is Canbridge Pharmaceuticals' Gross Margin % too high?
Canbridge Pharmaceuticals' current Gross Margin % of 78.98% is 27% above median its 10-year median of 62.37. Over the past 10 years, this metric has ranged from a low of 57.16 to a high of 74.70. The Biotechnology industry median Gross Margin % is 60.91. Canbridge Pharmaceuticals' value of 78.98% is 29.7% above this industry median. Based on the distribution chart, Canbridge Pharmaceuticals ranks #250 out of 733 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Canbridge Pharmaceuticals has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Canbridge Pharmaceuticals' Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Canbridge Pharmaceuticals ranks #250 out of 733 companies for Gross Margin %. This puts Canbridge Pharmaceuticals in the upper half of its industry. The industry median Gross Margin % is 60.91. Canbridge Pharmaceuticals' value of 78.98% is 29.7% above this benchmark. Historically, Canbridge Pharmaceuticals' own Gross Margin % has ranged from 57.16 to 74.70 over the past decade. While the company's 10-year median is 62.37 vs. the industry median of 60.91, Canbridge Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 733 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Canbridge Pharmaceuticals's current Gross Margin % of 78.98% is 29.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Canbridge Pharmaceuticals and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Canbridge Pharmaceuticals's current Gross Margin % is 78.98%, which is 27% above median its own 10-year median of 62.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Canbridge Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Canbridge Pharmaceuticals (HKSE:01228) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.38, compared to a current price of HK$2.05 — trading 439.5% above its estimated fair value. The current Gross Margin % is 78.98%, which is 27% above median its 10-year median of 62.37 and 29.7% above the Biotechnology industry median of 60.91. Canbridge Pharmaceuticals' overall GF Score™ is 48/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Canbridge Pharmaceuticals (HKSE:01228), the current Gross Margin % is 78.98% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Canbridge Pharmaceuticals (HKSE:01228) Overvalued in 2026?
Based on GuruFocus' analysis, Canbridge Pharmaceuticals stock appears to be overvalued.
The current stock price of HK$2.05 is trading 439.5% above its estimated GF Value™ of HK$0.38.
GuruFocus considers Canbridge Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for HKSE:01228:
Gross Margin %: 78.98% (27% above median its 10-year median of 62.37)
GF Value™: HK$0.38 vs. price of HK$2.05 (439.5% above fair value)
Industry Position: 29.7% above the Biotechnology median (#250 of 733)
No single metric tells the full story. See the HKSE:01228 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Canbridge Pharmaceuticals Inc is a biotechnology company engaged in the research, development, and commercialization of therapies targeting rare diseases. Its differentiated portfolio of therapeutics includes biologics, small molecules, and gene therapies, targeting prevalent rare disease indications that have unmet needs and market potential. The Group's portfolio is composed of approved products like Hunterase, Livmarli, and Gaurunning, and various assets currently in development like CAN106, CAN107, CAN104, and CAN105, all these targeting diseases such as Hunter syndrome and other lysosomal storage disorders, paroxysmal nocturnal hemoglobinuria, hemophilia A, metabolic disorders, rare cholestatic liver diseases, and neuromuscular diseases. The Group's main market is Mainland China.
48GF Score
Get the complete analysis for HKSE:01228
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01228 has been successfully added to your 
